Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma

Saburi, Masuho; Ogata, Masao; Soga, Yasuhiro; Kondo, Yoshiyuki; R, Kurimoto; Itani, Kazuhito; Kohno, Kazuhiro; Uchida, Hajime; Nakayama, Toshiyuki

doi:10.3960/jslrt.19031

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic strategy for AMM has not yet been established. Some reported cases were successfully treated with myeloma-targeting agents such as proteasome inhibitors and/or immunomodulatory agents [ 5 , 7 ]; in contrast, other cases have been reported to be refractory to such novel agents [ 6 , 18 ]. Although conventional chemotherapy is effective for short-term disease control [2] , it is scarcely results in long-term remission.…”

Section: Discussionmentioning

confidence: 99%

Anaplastic multiple myeloma with MYC rearrangement

Ichikawa

Fukuhara

Hashimoto

et al. 2022

Leukemia Research Reports

View full text Add to dashboard Cite

A 52-year-old man with rapidly progressive paraplegia was presented to us with paravertebral tumors. Laminectomy with tumor resection was performed, and pathological analysis of the tumor revealed compact proliferation of anaplastic plasmacytoid cells. G-band analysis of the tumor revealed a complex karyotype, including IgH/MYC translocation. The patient was diagnosed with anaplastic multiple myeloma (AMM) with MYC arrangement, and cytotoxic chemotherapy followed by autologous hematopoietic stem cell transplantation resulted in long-term disease-free remission. This is the first report describing a case of de novo AMM with MYC rearrangement, suggesting that conventional chemotherapy could be a treatment option for this formidable disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Anaplastic multiple myeloma with MYC rearrangement

Ichikawa

Fukuhara

Hashimoto

et al. 2022

Leukemia Research Reports

View full text Add to dashboard Cite

show abstract

“…Classification of myeloma risk using the international staging system (ISS) and host factors such as age, performance status, and comorbidities are considered important for determining prognosis and choosing treatment options (7) . However, many parameters were suggested for these purposes, some concern demographic characteristics as age, residence, gender, race, or obesity (8)(9)(10) , others are related to diagnostic results as radiology or laboratory findings as Hb, plasma cells, renal insufficiency, hypercalcemia, β2microglobulin, free light chain, Parathyroid hormone, PTH, or immunofixation tests (11)(12)(13)(14)(15)(16)(17) .…”

Section: Introductionmentioning

confidence: 99%

Progression and Free Progression Survival Indices in Patients with Multiple Myeloma

Sadik A. Abdullah,

Waseem F. Al-Tameemi,

Ghassan A.A. Al-Shamma

2021

MLU

View full text Add to dashboard Cite

The main feature in multiple myeloma is osteolysis and, hence, bone turnover markers have got the at most care in different studies on this disease. The present paper would stress on the calculation of free progression survival indices using some of these markers .Sixty-five MM (males=41, females=24) patients distributed to different hematologycenters in Iraq were enrolled in this study. Their age range was 39-81 years, they were distributed all on three stages of the diseaseaccording to the international staging system (ISS) : Group A -Stage I (n=21 patients, age mean 57.14±12.25 years), Group B -Stage II (n=22 patients, age mean of 56.45±11.33 years), and Group C-Stage III (n=22 patients, age mean 60.59±11.55 years). Blood samples were taken from each patient just prior to starting the chemotherapy for the measurement of blood hemoglobin (Hb), serum Creatinine, Calcium, β2 Microglubulin, Osteocalcin (OC), total and Beta C-terminal telopeptide (CTX, BCTX), Parathyroid hormone (PTH), Syndecan-1 (CD138), and both kappa & lambda free light chain (FLCк, FLCλ).There was no significant association between age, sex, body weight and residency with disease staging or progression. From the bone markers studied only CTX and BCTX were significantly associated with the disease progression and showing varying free progression patient survival times with CTX and BCTX at different concentrations.The comparison between the results of the newly diagnosed and long-standing patients revealed that only total FLC, FLCк, FLCλ and CD138 were significantly higher in the long-standing patients. Their sensitivity and specificity values were varying among these markers.

show abstract

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy

Tang

Xiang

2020

Ann Hematol

View full text Add to dashboard Cite

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma

Cited by 4 publications

References 21 publications

Anaplastic multiple myeloma with MYC rearrangement

Anaplastic multiple myeloma with MYC rearrangement

Progression and Free Progression Survival Indices in Patients with Multiple Myeloma

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy

Contact Info

Product

Resources

About